Search Results - "Brady, William E"

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study by Farley, John, Prof, Brady, William E, PhD, Vathipadiekal, Vinod, PhD, Lankes, Heather A, PhD, Coleman, Robert, Prof, Morgan, Mark A, Prof, Mannel, Robert, Prof, Yamada, S Diane, Prof, Mutch, David, Prof, Rodgers, William H, Prof, Birrer, Michael, MD, Gershenson, David M, MD

“…Summary Background Low-grade serous carcinoma of the ovary is chemoresistant but mutations in the MAPK pathway could be targeted to control tumour growth. We…”
Get full text

Efficacy and safety of bevacizumab in recurrent sex cord‐stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group by Brown, Jubilee, Brady, William E., Schink, Julian, Le, Linda, Leitao, Mario, Yamada, S. Diane, Geest, Koen, Gershenson, David M.

“…BACKGROUND The Gynecologic Oncology Group conducted this phase 2 trial to estimate the antitumor activity of bevacizumab and to determine the nature and degree…”
Get full text

Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study by Alvarez, Edwin A, Brady, William E, Walker, Joan L, Rotmensch, Jacob, Zhou, Xun C, Kendrick, James E, Yamada, S. Diane, Schilder, Jeanne M, Cohn, David E, Harrison, Charles R, Moore, Kathleen N, Aghajanian, Carol

“…Abstract Objective This two-stage phase II study was designed to assess the activity of the combination of temsirolimus and bevacizumab in patients with…”
Get full text

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial by Pearson, Thomas A, Denke, Margo A, McBride, Patrick E, Battisti, Wendy P, Brady, William E, Palmisano, Joanne

“…To determine the extent of reduction in low-density lipoprotein cholesterol (LDL-C) level and improvement in National Cholesterol Education Program Adult…”
Get more information

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study by Schilder, Russell J, Brady, William E, Lankes, Heather A, Fiorica, James V, Shahin, Mark S, Zhou, Xun C, Mannel, Robert S, Pathak, Harsh B, Hu, Wei, Alpaugh, R. Katherine, Sood, Anil K, Godwin, Andrew K

“…Abstract Objectives Preclinical data suggest an important role for the sarcoma proto-oncogene tyrosine kinase (SRC) in the oncogenesis of epithelial ovarian…”
Get full text

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study by Campos, Susana M, Brady, William E, Moxley, Katherine M, O'Cearbhaill, Roisin E, Lee, Paula S, DiSilvestro, Paul A, Rotmensch, Jacob, Rose, Peter G, Thaker, Premal H, O'Malley, David M, Hanjani, Parviz, Zuna, Rosemary E, Hensley, Martee L

“…Abstract Objective Carcinosarcomas of the female genital tract, also called malignant mixed müllerian tumors, are aggressive biphasic tumors. Second-line…”
Get full text

A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study by Gold, Michael A, Brady, William E, Lankes, Heather A, Rose, Peter G, Kelley, Joseph L, De Geest, Koen, Crispens, Marta A, Resnick, Kimberly E, Howell, Stephen B

“…Abstract Purpose This multi-institutional phase II trial assessed the activity and tolerability of the anti-metastatic A6 peptide that binds CD44 in patients…”
Get full text

Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients by Catapano, Alberico L., Davidson, Michael H., Ballantyne, Christie M., Brady, William E., Gazzara, Russell A., Tomassini, Joanne E., Tershakovec, Andrew M.

“…ABSTRACT Objective: To assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved…”
Get full text

Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study by Darcy, Kathleen M, Brady, William E, Blancato, Jan K, Dickson, Robert B, Hoskins, William J, McGuire, William P, Birrer, Michael J

“…Abstract Objective The Gynecologic Oncology Group (GOG) examined the prognostic relevance of c-MYC amplification and polysomy 8 in epithelial ovarian cancer…”
Get full text

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial by Gershenson, David M, Miller, Austin, Brady, William E, Paul, James, Carty, Karen, Rodgers, William, Millan, David, Coleman, Robert L, Moore, Kathleen N, Banerjee, Susana, Connolly, Kate, Secord, Angeles Alvarez, O'Malley, David M, Dorigo, Oliver, Gaillard, Stephanie, Gabra, Hani, Slomovitz, Brian, Hanjani, Parviz, Farley, John, Churchman, Michael, Ewing, Ailith, Hollis, Robert L, Herrington, C Simon, Huang, Helen Q, Wenzel, Lari, Gourley, Charlie

“…Low-grade serous carcinoma of the ovary or peritoneum is characterised by MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to…”
Get full text

Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001) by Konstantinopoulos, Panagiotis A., Brady, William E., Farley, John, Armstrong, Amy, Uyar, Denise S., Gershenson, David M.

“…To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. Patients with recurrent…”
Get full text

An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor by Gore, Martin, Hackshaw, Allan, Brady, William E., Penson, Richard T., Zaino, Richard, McCluggage, W. Glenn, Ganesan, Raji, Wilkinson, Nafisa, Perren, Timothy, Montes, Ana, Summers, Jeffrey, Lord, Rosemary, Dark, Graham, Rustin, Gordon, Mackean, Melanie, Reed, Nicholas, Kehoe, Sean, Frumovitz, Michael, Christensen, Helen, Feeney, Amanda, Ledermann, Jonathan, Gershenson, David M.

“…We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer. We conducted a multicenter randomized factorial trial (UK…”
Get full text

Impact of Robotics and Laparoscopy on Surgical Skills: A Comparative Study by Guru, Khurshid A., MBBS, Kuvshinoff, Boris W., MD, FACS, Pavlov-Shapiro, Sasha, MD, Bienko, Marlene B., RN, Aftab, Mehr N., BA, Brady, William E., MS, Mohler, James L., MD, FACS

“…Background This study objectively surveyed and compared the ability of participants to perform laparoscopic and robotic tasks, and attempted to determine the…”
Get full text

Is adjuvant chemotherapy indicated in ovarian immature teratomas? A combined data analysis from the Malignant Germ Cell Tumor International Collaborative by Pashankar, Farzana, Hale, Juliet P., Dang, Ha, Krailo, Mark, Brady, William E., Rodriguez‐Galindo, Carlos, Nicholson, James C., Murray, Matthew J., Bilmire, Deborah F., Stoneham, Sara, Arul, G. Suren, Olson, Thomas A., Stark, Daniel, Shaikh, Furqan, Amatruda, James F., Covens, Allan, Gershenson, David M., Frazier, A. Lindsay

“…BACKGROUND There is a debate regarding the management of ovarian immature teratomas (ITs). In adult women, postoperative chemotherapy is standard except for…”
Get full text

Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study by Huh, Warner K., Brady, William E., Fracasso, Paula M., Dizon, Don S., Powell, Matthew A., Monk, Bradley J., Leath, Charles A., Landrum, Lisa M., Tanner, Edward J., Crane, Erin K., Ueda, Stefanie, McHale, Michael T., Aghajanian, Carol

“…Women with persistent, recurrent, and/or metastatic cervical cancer have a poor prognosis. Even with the availability of cisplatin plus paclitaxel and…”
Get full text

Minority participation in Gynecologic Oncology Group (GOG) Studies by Scalici, Jennifer, Finan, Michael A, Black, Jennifer, Harmon, Mary Danner, Nicolson, William, Lankes, Heather A, Brady, William E, Rocconi, Rodney P

“…Abstract Objective Participation of minority populations in clinical trials is paramount to understanding and overcoming cancer racial disparities. The goal of…”
Get full text

Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial by Pearson, Thomas A, Denke, Margo A, McBride, Patrick E, Battisti, Wendy P, Gazzara, Russell A, Brady, William E, Palmisano, Joanne

“…To examine whether the improvements in lipid profiles and low-density lipoprotein cholesterol (LDL-C) goal attainment found in the Ezetimibe Add-On to Statin…”
Get more information

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial by Farley, John H, Brady, William E, O'Malley, David, Fujiwara, Keiichi, Yonemori, Kan, Bonebrake, Albert, Secord, Angeles Alvarez, Stephan, Jean-Marie, Walker, Joan L, Nam, Joo-Hyun, Birrer, Michael J, Gershenson, David M

“…The primary objective of the study was to estimate the 12-month progression-free survival (PFS) for carboplatin/paclitaxel + temsirolimus in women with newly…”
Get full text

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience by Oliver, Kate E., Brady, William E., Birrer, Michael, Gershenson, David M., Fleming, Gini, Copeland, Larry J., Tewari, Krishnansu, Argenta, Peter A., Mannel, Robert S., Secord, Angeles Alvarez, Stephan, Jean-Marie, Mutch, David G., Stehman, Frederick B., Muggia, Franco M., Rose, Peter G., Armstrong, Deborah K., Bookman, Michael A., Burger, Robert A., Farley, John H.

“…•In early stage patients, PFS was better for OCCC than for SOC.•In late-stage patients, OCCC was significantly associated with decreased OS.•Treatment effect…”
Get full text

A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study by Thaker, Premal H., Brady, William E., Lankes, Heather A., Odunsi, Kunle, Bradley, William H., Moore, Kathleen N., Muller, Carolyn Y., Anwer, Khursheed, Schilder, Russell J., Alvarez, Ronald D., Fracasso, Paula M.

“…•Recurrent EOC patients were treated with GEN-1 and pegylated liposomal doxorubicin.•Three had partial responses and five had stable disease of the 16…”
Get full text